Comparing the current results to its competitors, Tc Biopharm Holdings Plc reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, slower than the combined decrease of the TCBP's competitors by -46.83 %, recorded in the same quarter.
Tc Biopharm Holdings Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and strong competition. It faces potential competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Its GD-T cell therapeutic candidates compete with existing and future products in oncology and viral indications. The company holds foundational intellectual property in co-stimulatory CAR technology, maintains GMP manufacturing capabilities, and has established banks of allogeneic products. Competitors in the cell therapy sector include AdicetBio, Bristol Myers Squibb, Editas Medicine, and Sangamo Therapeutics, some of which have agreements among themselves. The company asserts that its GD-T cell therapeutic candidates offer a distinct commercial proposition compared to these competitors.
Beam Therapeutics Inc's business model revolves around developing precision genetic medicines using base editing technology. They aim to address genetic diseases by making precise edits to a patient's DNA at the molecular level, providing potential treatments that are highly targeted and minimally invasive.
Adaptive Biotechnologies Corporation is a biotechnology company that utilizes its proprietary immune medicine platform to decode and analyze the human immune system. Their business model focuses on providing solutions for the diagnosis, monitoring, and treatment of various diseases such as cancer and infectious diseases. By leveraging genomics and machine learning technologies, they aim to create personalized immunotherapies and diagnostics to improve patient outcomes.
Cellectis S is a biotechnology company that operates using a business model focused on developing and commercializing gene editing technologies. They utilize a proprietary platform called TALEN® to modify genes for various applications in agriculture, healthcare, and biomanufacturing. By providing innovative solutions through gene editing, Cellectis aims to address critical challenges in these industries and create value for their customers and stakeholders.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Tc Biopharm holdings Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tc Biopharm holdings Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
